HOW THE ARORA REPORT IDENTIFIED GUARANT HEALTH BEFORE WALL STREET CAUGHT ON — THE GAIN HAS NOW REACHED 512%
By Nigam Arora
Guardant Health Inc. (GH), a cancer-detection company that The Arora Report recommended at an average price of $26.34, is trading at $161.26 as of this writing after jumping over 10% following the release of its second-quarter results, bringing the gain for members who followed the signal to approximately 512%.
The magnitude of the gain naturally attracts attention, but serious investors should not look at Guardant Health simply as a stock that happened to rise several hundred percent. The more important lesson is how an investor can identify a major change early, before the change becomes obvious to Wall Street, before the favorable narrative becomes widely accepted, and before a stock’s success is repeatedly discussed in the financial media.… Please click here or the title below to read more.